Since R-2-HG inhibits TET2 enzymatic activity, it has been hypothesized that the effects of mutated IDH in AML are mainly due to R-2-HG-mediated TET2 inhibition and the consequent alterations to DNA methylation at the level of stem/progenitor myeloid cells [89]. The gene discussed is TET2; the disease is acute myeloid leukemia.